🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Chronic Airway Disease and Multimorbidity Cohort

Recruitingn/aAges 18 Years - anyAllChina-Japan Friendship Hospital
NCT06798077 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated. Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with chronic obstructive pulmonary disease ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age; * The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis". Exclusion Criteria: * Patients were unable to undergo spirometry during the stabilization period; * Expected survival is less than 1 month; * Refusal to sign an informed consent form; * Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion; * Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation.
💊

What it tests

  • Not listed
📍

Where

9 sites
National Center for Respiratory Medicine, China-Japan Friendship Hospital
Beijing, China
Zhujiang Hospital of Southern Medical University
Guangzhou, China
Henan Provincial People's Hospital
Zhengzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
The Second Xiangya Hospital of Central South University
Changsha, China
The First Affiliated Hospital of China Medical University
Shenyang, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, China

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy